GeneCentric Data Suggest Fragmentomics Could Expand Liquid Biopsy Beyond Mutation Testing
Presentations at AACR 2026 will showcase fragmentomics-based technology for detecting therapeutic markers and providing prognostic insight.
Presentations at AACR 2026 will showcase fragmentomics-based technology for detecting therapeutic markers and providing prognostic insight.
The collaboration allows clinicians to order the Galleri test and view results directly within existing electronic health record workflows.
Agilent Technologies will acquire Biocare Medical for $950 million in cash, adding more than 300 specialized antibodies and expanding Agilent’s pathology and immunohistochemistry offerings, according to the companies.
A Florida jury sides with American Clinical Solutions in a long-running reimbursement dispute with Blue Cross Blue Shield of Puerto Rico.
Read MoreThe deal positions Abbott to enter the US cancer screening and precision oncology diagnostics market with products including Cologuard and Oncotype DX tests.
Read MoreThe association’s incoming CEO brings more than two decades of leadership experience in global health, nonprofit management, and the scientific community.
Read MoreThe deal adds a solid-phase cytometry platform that delivers sterility test results in four days versus a traditional 14-day incubation period.
Read MoreThe recipient is recognized for contributions to molecular diagnostics and women’s health screening technologies.
Read MoreThe laboratory services company updates full-year guidance following continued momentum in diagnostics and central laboratory businesses.
Read MoreThe 18,000-sq-ft facility will support the expansion of immunogenicity testing and target binding technologies.
Read MoreTeams complete whole human genome sequencing and analysis in under four hours, demonstrating potential for same-day NICU workflows.
Read MoreThe new interim CEO currently serves as senior vice president and chief operating officer at the organization.
Read MoreThe extended agreement through 2032 broadens commercial rights beyond the recently launched carrier screening kit to accelerate diagnostic innovation.
Read MoreThe joint consensus recommendation from AMP, ASCO, and CAP addresses variability in molecular profiling report formats across laboratories.
Read MoreThe proteomics company will use capital to advance partner-driven product development and commercial operations from new California headquarters.
Read MoreThe new Louisville campus aims to deliver next-morning molecular diagnostic results to 5 million patient samples annually nationwide.
Read MoreThe Alzheimer’s diagnostics company will relocate headquarters and expand CLIA-certified lab operations to the Cortex Innovation District by late 2026.
Read MoreThe deal includes customer accounts and operating assets focused on cancer-related clinical testing services across the United States.
Read More